# Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

> **NCT01623713** · PHASE2 · COMPLETED · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 260 (actual)

## Conditions studied

- Schizophrenia
- Iloperidone
- Efficacy

## Interventions

- **DRUG:** iloperidone
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT01623713
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-10
- **Final completion:** 2013-11
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2013-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01623713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01623713, "Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01623713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*